Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: December 2010

Chapter 5 - Paroxysmal headaches

Summary

According to the criteria of the International Headache Society (IHS), a migraine is defined as a disease with periodic occurring headache episodes, typically associated with autonomic symptoms. The release of neuropeptides explains the actual origin of pain but not how and why the attack begins so abruptly in humans. Triptans improves the typical additional symptoms like nausea or vomiting, photo- and photophobia, and improves the ability to return to work. During a migraine attack, most patients suffer from gastrointestinal symptoms. The aim of migraine prophylaxis is a reduction of frequency, severity and duration of migraine attacks and the prevention of medication overuse headache. Effective for preventive migraine therapy are the non-selective beta-blocker propranolol and the beta-1-selective beta-blocker metoprolol. Most psychological treatments used in migraine therapy are behavior therapies. Paroxysmal pain of short duration located in a region of one of the trigeminus nerves is very characteristic for the trigeminal neuralgia.

Related content

Powered by UNSILO

References

BrandesJL, KudrowD, StarkSR, O’CarrollCP, AdelmanJU, O’DonnellFJ, AlexanderWJ, SpruillSE, BarrettPS, LenerSE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Jama 2007, 297(13):1443–54.
BussoneG, DienerH, PfeilJ, SchwalenS. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005, 59:961–968.
DahlöfC. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993, 13:166–171.
DienerHC, RechesA, PascualJ, JansenJ-P, PiteiD, Steiner T, on behalf of the Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002, 47:99–107.
DienerHC, LimmrothV. Medication-overuse headache: a worldwide problem. Lancet Neurology 2004, 3:475–483.
DienerH, PfaffenrathV, PagelerL, PeilH, AicherB. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005, 25:776–778.
DienerHC, LamplC, ReimnitzP, VoelkerM. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006, 6(4):563–73.
DienerHC, BussoneG, Van OeneJ, LahayeM, SchwalenS, GoadsbyPJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007, 27:814–823.
EdvinssonL, EkmanR, JansenI, McCullochJ, MortensenA, UddmanR. Reduced levels of calcitonin gene-related peptide-like immunoreactivity in human brain after subarachnoid haemorrhage. Neurosci Lett 1991, 121:151–154.
EdvinssonL, UddmanR. Immunohistochemical localization and dilatory effect of substance P on human cerebral vessels. Brain Res 1982, 232:466–471.
FerrariMD, RoonKI, LiptonRB, GoadsbyPJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668–1675.
GrahamJR, WolffHG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psych 1938, 39:737–763.
International Headache Society. The international classification of headache disorders. 2nd edn. Cephalalgia 2004, 24 (Suppl. 1):9–160.
KelmanL. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004, 44:865–872.
KelmanL. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007, 27(5):394–402.
KlapperJ, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17(2):103–108.
LiptonRB, StewartWF. Epidemiology and comorbidity of migraine. In: GoadsbyPJ, SilbersteinSD. (eds.). Headache. Boston: Butterworth-Heinemann, 1997, p. 75–97.
LiptonRB, BigalME, DiamondM, FreitagF, ReedML, StewartWF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68(5):343–9.
LucasC, ChaffautC, ArtazMA, Lanteri-MinetM. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 2005, 25(4):267–79.
MacGregorEA, FrithA, EllisJ, AspinallL, HackshawA. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006, 67(12):2159–63.
MannixLK, SavaniN, LandyS, ValadeD, ShackelfordS, AmesMH, JonesMW. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007, 47(7):1037–49.
MassiouH, BousserM-G. Influence of female hormones on migraine. In: OlesenJ, Tfelt-HansenP, WelchKMA. (eds.). The headaches. 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000, p. 261–267.
MathewNT, FinlaysonG, SmithTR, CadyRK, AdelmanJ, MaoL, WrightP, GreenbergSJ. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007, 47(2):189–98.
McNeelyW, GoaKL. Diclofenac-potassium in migraine. Drugs 1999, 57:991–1003.
MoskowitzMA. The neurobiology of vascular head pain. Ann Neurol 1984, 16:157–168.
OlesenJ, DienerH, HusstedtIW, GoadsbyPJ, HallD, MeierU, PollentierS, LeskoLM, for the BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 2004, 350:1104–1110.
Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994, 44:1353–1354.
SchoonmanGG, EversDJ, TerwindtGM, van DijkJG, FerrariMD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 2006, 26(10):1209–13.
SilbersteinSD. Migraine and women. The link between headache and hormones. Postgrad Med 1995, 97:147–153.
SilbersteinSD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754–762.
SilbersteinSD, LiptonRB, DodickDW, FreitagFG, RamadanN, MathewN, BrandesJL, BigalM, SaperJ, AscherS, JordanDM, GreenbergSJ, HulihanJ. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47(2):170–80.
SteinerTJ, StewartWF, KolodnerK, LibermanJ, LiptonRB. Epidemiology of migraine in the England. Cephalalgia 1999, 19:305–306.
Tfelt-HansenP, SaxenaPR, DahlöfC, PascualJ, LainezM, HenryP, DienerHC, SchoenenJ, FerrariMD, GoadsbyPJ. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000, 123:9–18.
TitusF, LainezJ, LeiraR, DiezE, MonteiroP, DexeusI. Double-blind, multicentric, comparative study of lysin acetylsalicylate (1620 mg equivalent to 900 mg aspirin) + metoclopramide (10 mg) versus ergotamine (2 mg) + caffeine (200 mg) in the treatment of migraine. Cephalalgia 1999, 19:371.
van de VenRC, KajaS, PlompJJ, FrantsRR, Van Den MaagdenbergAM, FerrariMD. Genetic models of migraine. Arch Neurol 2007, 64(5):643–6.
WeillerC, MayA, LimmrothV, JüptnerM, KaubeH, van SchayckR, CoenenHH, DienerHC. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995, 1:658–660.
WelchKMA, MathewMT, StoneP, RosamondW, SaiersJ, GuttermanD. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000, 20:687–695.
WessmanM, TerwindtGM, KaunistoMA, PalotieA, OphoffRA. Migraine: a complex genetic disorder. Lancet Neurol 2007, 6(6):521–32.